Search Results for "vaccine, MMR"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, MMR. Results 1 to 4 of 4 total matches.
See also: MMR II, MMRV, ProQuad

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
not have evidence of immunity to rubella should receive a dose of MMR vaccine postpartum, before discharge ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Dostarlimab (Jemperli) for Endometrial Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
, blocking its interaction with PD-L1 and PD-L2 and restoring T cell antitumor immune responses. dMMR ...
The FDA has granted regular approval to dostarlimabgxly (Jemperli – GSK), an immune checkpoint inhibitor, for treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation. Dostarlimab received accelerated approval in 2021 for treatment of adults with dMMR recurrent or advanced endometrial cancer or nonendometrial solid tumors that progressed on or following prior treatment and who have no...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-5   doi:10.58347/tml.2023.1673h |  Show IntroductionHide Introduction

In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
immune responses. dMMR tumors are more responsive to PD-1 blockade than mismatch repair-proficient ...
The immune checkpoint inhibitor dostarlimab-gxly (Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab was recently granted regular approval for treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e138   doi:10.58347/tml.2023.1683f |  Show IntroductionHide Introduction

Expanded Table: Some Vaccines for Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
during or after 1980 without evidence of immunity (documentation of vaccination, laboratory evidence ...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e170-3 |  Show IntroductionHide Introduction